Your session is about to expire
← Back to Search
Combination Therapy for Melanoma
Study Summary
This trial is testing how well radiation therapy, plasma exchange, and either pembrolizumab or nivolumab work in treating patients with melanoma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I can take care of myself but can't do heavy physical work.A technician can easily access my veins for treatment.You have been diagnosed with melanoma, and the diagnosis needs to be confirmed by the Mayo Clinic before participating in the trial.My cancer can be measured by tests or seen on scans.I am currently taking biotin supplements.Your sPD-L1 level is less than 1.7 ng/ml as tested by ELISA.I am not willing to use birth control.Your sPD-L1 levels measured by a specific test are higher than 1.7 ng/ml.
- Group 1: Treatment (radiation therapy, plasma exchange, immunotherapy)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has Pembrolizumab been examined in any other research projects?
"Currently, 1633 studies are in progress studying Pembrolizumab with 200 of them being Phase 3 trials. Houston, Texas is a major centre for these clinical investigations but there are over 73,000 sites conducting experiments concerning this medication worldwide."
What goals is this research attempting to achieve?
"The principal outcome that will be monitored for up to 24 months is the feasibility of this treatment regimen. Secondary objectives include assessing progression-free survival, overall response rate and overall survival via Kaplan-Meier estimates."
What is the cap on the number of participants in this medical experiment?
"Yes, the information on clinicaltrials.gov affirms that this scientific exploration is currently accepting applicants. It was initially advertised in December of 2020 and most recently updated in May 2022. The experiment is accommodating 20 subjects across a single site."
What indications is Pembrolizumab routinely prescribed for?
"Pembrolizumab is a viable treatment for unresectable melanoma, as well as microsatellite instability high and squamous cell carcinoma cases with a heightened risk of recurrence."
Does this clinical experiment currently admit participants?
"Per the data posted on clinicaltrials.gov, this study is actively enrolling participants and has been since December 14th 2020 (latest update - 5 May 2022)."
Share this study with friends
Copy Link
Messenger